Latest news with #DatavantConnect
Business Wire
15-05-2025
- Business
- Business Wire
Datavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected Data
NEW YORK--(BUSINESS WIRE)--Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Aetion, a leading real-world evidence (RWE) platform that powers critical decision-making in healthcare. With this acquisition, Aetion will join Datavant to deliver an end-to-end RWE platform, enabling healthcare and life sciences companies to more efficiently answer research questions about the clinical impact of therapies in development and in market. The companies will focus on leveraging their complementary capabilities to create an end-to-end offering on data discovery, linkage, privacy, curation and advanced analysis to enable their life sciences customers to create analytics-ready insights. Share This complementary combination unites two leaders to make RWE truly actionable, covering the full spectrum of services needed to deliver scientifically validated, transparent and reproducible RWE accepted by global regulators, including the FDA and EMA. Aetion brings industry-leading technology, services and data partners to help life science and medical device customers develop decision-grade evidence plans and analyses. Stakeholders across the healthcare value chain use Datavant's industry-standard platform for secure, compliant health data exchange to fuel connected, comprehensive insights that empower smarter decisions and advance patient outcomes. 'As Datavant has grown and scaled, our life sciences and ecosystem partners have been asking us for a deeper capability set to bring together disparate data sources so they can tap into a more comprehensive and longitudinal view of patient health across the product lifecycle," said Kyle Armbrester, Chief Executive Officer, Datavant. 'The addition of Aetion's team of scientists and technologists further bolsters our complementary capabilities and expertise so we can better leverage data from our ecosystem of partners to support efforts before, during, and after commercialization - generating evidence from trial to treatment and beyond to deliver life-improving therapies.' The companies will focus on leveraging their complementary capabilities to create an end-to-end offering on data discovery, linkage, privacy, curation and advanced analysis to enable their ecosystem and life sciences partners to create analytics-ready insights. This announcement follows the launch of Datavant Connect powered by AWS Clean Rooms, an enhanced capability that facilitates cloud-first data discovery and evaluation to accelerate time to insight. Through Datavant Connect, ecosystem partners' data is more easily and equitably accessible and able to be combined with complementary data sources, thus unlocking additional value to partners and customers alike. Aetion greatly enhances the Datavant Connect platform's data discovery features, and will enhance privacy assessments and give end-customers clean datasets and analytics they can leverage for a range of uses. In addition, the Aetion Evidence Platform is now available in AWS Marketplace. This announcement also coincides with the launch of Aetion® Activate. Activate expands Aetion's software portfolio to better serve biostatisticians and data scientists, creating a collaborative, auditable, and secure platform for both code and no-code users. It also removes the burdens of manual, error-prone data preparation—freeing teams to focus on research and critical analysis. Together with Datavant's connectivity and tokenization capabilities, Aetion now offers a more integrated ecosystem for preparing and analyzing real-world data at scale. 'Our mission at Aetion has always been to power critical decisions in healthcare with data science-driven technology,' said Jeremy Rassen, ScD, CEO of Aetion. 'By joining forces with Datavant, we'll unlock the full potential of real-world evidence to advance confident, data-driven decisions that improve patient care. Today, we are taking a bold step toward realizing our shared vision: a world where health data is seamlessly connected and actionable—so we can answer what treatments work, for whom, and what they should cost.' Upon closing, Datavant and Aetion will have a combined ecosystem of over 300 data partners. Datavant's RWD partners comprise datasets across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more. With Aetion, RWD partners across the Datavant ecosystem will gain improved visibility of their data's utility through sharper querying of the datasets, scaling value, demand, and additional use cases across a more expansive base of life sciences companies. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Aetion Aetion® is a global healthcare technology company that delivers real-world evidence (RWE) solutions to biopharmaceutical companies, medical device manufacturers, payers, and regulators. Powered by Aetion Evidence Platform®, Aetion applies advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence on the safety, effectiveness, and value of medical treatments. Through this evidence-based approach, Aetion informs healthcare's most critical decisions—what works best, for whom, and when—while enabling scalable solutions for regulatory submissions, market access, and clinical development. Aetion's investors include Flare Capital Partners, NEA, Warburg Pincus, B Capital, and leading life sciences and payer organizations. Learn more at and follow us on LinkedIn.
Yahoo
15-05-2025
- Business
- Yahoo
Datavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected Data
Combination will enable faster, more actionable insights across the clinical and commercial lifecycle NEW YORK, May 15, 2025--(BUSINESS WIRE)--Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Aetion, a leading real-world evidence (RWE) platform that powers critical decision-making in healthcare. With this acquisition, Aetion will join Datavant to deliver an end-to-end RWE platform, enabling healthcare and life sciences companies to more efficiently answer research questions about the clinical impact of therapies in development and in market. This complementary combination unites two leaders to make RWE truly actionable, covering the full spectrum of services needed to deliver scientifically validated, transparent and reproducible RWE accepted by global regulators, including the FDA and EMA. Aetion brings industry-leading technology, services and data partners to help life science and medical device customers develop decision-grade evidence plans and analyses. Stakeholders across the healthcare value chain use Datavant's industry-standard platform for secure, compliant health data exchange to fuel connected, comprehensive insights that empower smarter decisions and advance patient outcomes. "As Datavant has grown and scaled, our life sciences and ecosystem partners have been asking us for a deeper capability set to bring together disparate data sources so they can tap into a more comprehensive and longitudinal view of patient health across the product lifecycle," said Kyle Armbrester, Chief Executive Officer, Datavant. "The addition of Aetion's team of scientists and technologists further bolsters our complementary capabilities and expertise so we can better leverage data from our ecosystem of partners to support efforts before, during, and after commercialization - generating evidence from trial to treatment and beyond to deliver life-improving therapies." The companies will focus on leveraging their complementary capabilities to create an end-to-end offering on data discovery, linkage, privacy, curation and advanced analysis to enable their ecosystem and life sciences partners to create analytics-ready insights. This announcement follows the launch of Datavant Connect powered by AWS Clean Rooms, an enhanced capability that facilitates cloud-first data discovery and evaluation to accelerate time to insight. Through Datavant Connect, ecosystem partners' data is more easily and equitably accessible and able to be combined with complementary data sources, thus unlocking additional value to partners and customers alike. Aetion greatly enhances the Datavant Connect platform's data discovery features, and will enhance privacy assessments and give end-customers clean datasets and analytics they can leverage for a range of uses. In addition, the Aetion Evidence Platform is now available in AWS Marketplace. This announcement also coincides with the launch of Aetion® Activate. Activate expands Aetion's software portfolio to better serve biostatisticians and data scientists, creating a collaborative, auditable, and secure platform for both code and no-code users. It also removes the burdens of manual, error-prone data preparation—freeing teams to focus on research and critical analysis. Together with Datavant's connectivity and tokenization capabilities, Aetion now offers a more integrated ecosystem for preparing and analyzing real-world data at scale. "Our mission at Aetion has always been to power critical decisions in healthcare with data science-driven technology," said Jeremy Rassen, ScD, CEO of Aetion. "By joining forces with Datavant, we'll unlock the full potential of real-world evidence to advance confident, data-driven decisions that improve patient care. Today, we are taking a bold step toward realizing our shared vision: a world where health data is seamlessly connected and actionable—so we can answer what treatments work, for whom, and what they should cost." Upon closing, Datavant and Aetion will have a combined ecosystem of over 300 data partners. Datavant's RWD partners comprise datasets across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more. With Aetion, RWD partners across the Datavant ecosystem will gain improved visibility of their data's utility through sharper querying of the datasets, scaling value, demand, and additional use cases across a more expansive base of life sciences companies. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Aetion Aetion® is a global healthcare technology company that delivers real-world evidence (RWE) solutions to biopharmaceutical companies, medical device manufacturers, payers, and regulators. Powered by Aetion Evidence Platform®, Aetion applies advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence on the safety, effectiveness, and value of medical treatments. Through this evidence-based approach, Aetion informs healthcare's most critical decisions—what works best, for whom, and when—while enabling scalable solutions for regulatory submissions, market access, and clinical development. Aetion's investors include Flare Capital Partners, NEA, Warburg Pincus, B Capital, and leading life sciences and payer organizations. Learn more at and follow us on LinkedIn. View source version on Contacts Media Contact Lynn ShepherdHead of Corporate Communications, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
13-05-2025
- Business
- Associated Press
OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the Datavant Connect platform to accelerate healthcare data discovery, analytics, and partner assessment processes. These new advancements will be presented by Datavant this week at ISPOR 2025, highlighting the importance of secure, scalable, and fit-for-purpose data solutions in driving innovation across healthcare and life sciences. The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value for clinical and scientific advancement. However, like crude oil, this raw data must be refined—its fragmented and siloed nature continues to hinder accessibility and usability. As healthcare and life sciences organizations increasingly seek targeted, fit-for-purpose datasets, scalable and secure technological solutions have become essential to unlocking its full potential. Leveraging AWS Clean Rooms, OneMedNet will offer sophisticated data partner assessment and discovery tools through the Datavant Connect platform, enabling secure collaboration environments without direct data movement or sharing of raw data. This 'no underlying data movement' approach significantly enhances data security and privacy, allowing for effective feasibility analyses between data sources and buyers. These advancements facilitate faster identification and evaluation of relevant healthcare datasets, directly addressing the industry's strategic, privacy, and data handling challenges. By empowering healthcare organizations with precise, secure, and efficient data access, OneMedNet accelerates the generation of valuable insights and transformative outcomes. 'Much of today's healthcare data remains untapped due to complexity and interoperability issues,' continued Aaron Green. 'Datavant Connect powered by AWS Clean Rooms effectively removes these barriers, positioning OneMedNet as an indispensable partner for organizations aiming to fully harness the potential of healthcare data.' About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. OneMedNet Contacts: Michael Wong, VP Marketing Email: [email protected] SOURCE: ONEMEDNET CORPORATION
Yahoo
13-05-2025
- Business
- Yahoo
OneMedNet Enhances Data Discovery and Analytics with the Datavant Connect platform and Amazon Web Service (AWS) Clean Rooms
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ('OneMedNet' or the 'Company'), the leading provider of regulatory-grade imaging Real-World Data (iRWD) today has announced its adoption of expanded capabilities within the Datavant Connect platform to accelerate healthcare data discovery, analytics, and partner assessment processes. These new advancements will be presented by Datavant this week at ISPOR 2025, highlighting the importance of secure, scalable, and fit-for-purpose data solutions in driving innovation across healthcare and life sciences. The healthcare industry has experienced a tremendous volume of health-related data generation—extending beyond patient interactions to include genomic sequencing, biomarker data, and more. In many ways, data has become the new oil, holding immense value for clinical and scientific advancement. However, like crude oil, this raw data must be refined—its fragmented and siloed nature continues to hinder accessibility and usability. As healthcare and life sciences organizations increasingly seek targeted, fit-for-purpose datasets, scalable and secure technological solutions have become essential to unlocking its full potential. Leveraging AWS Clean Rooms, OneMedNet will offer sophisticated data partner assessment and discovery tools through the Datavant Connect platform, enabling secure collaboration environments without direct data movement or sharing of raw data. This 'no underlying data movement' approach significantly enhances data security and privacy, allowing for effective feasibility analyses between data sources and buyers. These advancements facilitate faster identification and evaluation of relevant healthcare datasets, directly addressing the industry's strategic, privacy, and data handling challenges. By empowering healthcare organizations with precise, secure, and efficient data access, OneMedNet accelerates the generation of valuable insights and transformative outcomes. "Much of today's healthcare data remains untapped due to complexity and interoperability issues," continued Aaron Green. "Datavant Connect powered by AWS Clean Rooms effectively removes these barriers, positioning OneMedNet as an indispensable partner for organizations aiming to fully harness the potential of healthcare data." About OneMedNet Corporation OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption. Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. OneMedNet Contacts: Michael Wong, VP Marketing Email: SOURCE: ONEMEDNET CORPORATIONError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
05-05-2025
- Business
- Business Wire
Datavant and Boehringer Ingelheim Expand Partnership to Fuel Scalable Real-World Evidence Infrastructure
NEW YORK--(BUSINESS WIRE)-- Datavant, the leading health data platform company, today announced an expanded collaboration with Boehringer Ingelheim to support the pharmaceutical company's growing real-world evidence (RWE) initiatives. Through this partnership, Boehringer Ingelheim will leverage Datavant's privacy-preserving tokenization and data connectivity technologies to enhance clinical development and launch strategies across 75 additional clinical trials and multiple new molecular entities (NMEs). By leveraging Datavant Connect, powered by AWS Clean Rooms, Boehringer Ingelheim will be able to efficiently explore and assess third-party data sources without moving or sharing underlying data—streamlining data discovery, transformation, and linkage. This collaboration underscores the critical role of secure, connected data in driving more comprehensive insights into the patient journey. By leveraging Datavant Connect powered by AWS Clean Rooms, Boehringer Ingelheim will be able to efficiently explore and assess third-party data sources without moving or sharing underlying data—streamlining data discovery, transformation, and linkage within its own secure research environment. Arnaub Chatterjee, GM and President, Life Sciences, Ecosystem and Public Sector at Datavant, highlighted the transformative impact of the collaboration, "We are honored to support Boehringer Ingelheim in revolutionizing patient care through a pioneering data strategy. By enabling secure and efficient data linkage at scale, Boehringer Ingelheim is setting a new benchmark for medical research. This partnership exemplifies how technology can reshape healthcare and improve patient outcomes." By implementing Datavant's technology across a broad portfolio of trials and launches, Boehringer Ingelheim aims to accelerate the integration of real-world data into drug development, enabling more precise insights into treatment effectiveness, economic impact, and long-term health outcomes. Paul Petraro, Executive Director and Head of the Real World Evidence Analytics Center of Excellence at Boehringer Ingelheim, emphasized the significance of this initiative. "Our investment in real-world data underscores Boehringer Ingelheim's commitment to using cutting-edge technologies to advance medical research. By expanding this approach across more trials and commercial launches, we are positioned to drive more personalized and cost-effective treatments, ultimately transforming patient care," said Petraro. To ensure seamless integration with Boehringer Ingelheim's existing research infrastructure, teams will implement tokenization in a phased rollout. The collaboration aims to establish a robust framework to guide future studies and demonstrate the value to industry peers seeking to adopt a real-world evidence strategy based in cloud-first tokenization and data discovery. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Discover more at
